IXICO (LSE:IXI) Buildings And Improvements: £0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is IXICO Buildings And Improvements?

IXICO LSE:IXI Buildings And Improvements is £0.00 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

IXICO's quarterly buildings and improvements increased from Mar. 2025 (£0.00 Mil) to Sep. 2025 (£0.99 Mil) but then declined from Sep. 2025 (£0.99 Mil) to Mar. 2026 (£0.00 Mil).

IXICO's annual buildings and improvements increased from Sep. 2023 (£0.97 Mil) to Sep. 2024 (£0.97 Mil) and increased from Sep. 2024 (£0.97 Mil) to Sep. 2025 (£0.99 Mil).

IXICO Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for IXICO's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IXICO Buildings And Improvements Chart

IXICO Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 0.96 0.97 0.97 0.99

IXICO Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.97 0.00 0.99 0.00

IXICO Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of £0.00 Mil mean?
IXICO (LSE:IXI) has a Buildings And Improvements of £0.00 Mil as of Mar. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on IXICO and its competitors.
Is IXICO's Buildings And Improvements too high?
IXICO's current Buildings And Improvements is £0.00 Mil.
How does IXICO's Buildings And Improvements compare to VRTX and REGN?
IXICO's Buildings And Improvements of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Biotechnology company?
A good Buildings And Improvements depends on the Biotechnology industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on IXICO and its competitors. IXICO's current Buildings And Improvements is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IXICO stock overvalued right now?
Based on GuruFocus' analysis, IXICO (LSE:IXI) is currently considered Fairly Valued. The stock's GF Value™ is £0.08, compared to a current price of £0.08 — trading 6.3% below its estimated fair value. The current Buildings And Improvements is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For IXICO (LSE:IXI), the current Buildings And Improvements is £0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IXICO Business Description

Address 15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC provides neuroscience imaging and biomarker analytics services, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. It operates as an imaging contract research organization, supporting clinical trials for neurological disorders by processing and analyzing imaging data. Its platform is used to measure biomarkers associated with diseases such as Alzheimer's, Huntington's, and Parkinson's.